Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | SI | P14410 | 2/20 | 0.53 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.53 |
| ▸ | CBFB | Q13951 | 4/20 | 0.53 |
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179162 | 0.88 | MGAM (0.61) | MGAMGAASIMGAM2AMY1A | |
| SCHEMBL124239 | 0.83 | F2 (0.52) | MGAMGAASIMGAM2CBFB | |
| SCHEMBL31429762 | 0.80 | GAA (0.66) | MGAMGAASIMGAM2AMY1A | |
| SCHEMBL15779786 | 0.80 | CBFB (0.53) | CBFBSLC2A1NPC1KDM4EALDH1A1 | |
| SCHEMBL19205885 | 0.79 | GUSB (0.55) | MGAMGAASIMGAM2AMY1A | |
| SCHEMBL125632 | 0.79 | CBFB (0.82) | CBFBSLC2A1NPC1KDM4ERAB9A | |
| SCHEMBL126324 | 0.79 | CBFB (0.82) | CBFBSLC2A1NPC1KDM4EALDH1A1 | |
| SCHEMBL7278247 | 0.77 | MGAM (0.55) | MGAMGAASIMGAM2AMY1A | |
| SCHEMBL10746410 | 0.77 | PDE2A (0.52) | MGAMGAASIMGAM2AMY1A | |
| SCHEMBL10739533 | 0.76 | MGAM (0.57) | MGAMGAASIMGAM2AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | MGAM 2730/4885GAA 4268/4885SI 2384/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | MGAM 2694/4885GAA 4210/4885SI 2361/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | MGAM 2694/4885GAA 4210/4885SI 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.